Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

S.S. Ramalingam,T.-E. Ciuleanu,R. Bernabe Caro, M. Nishio,H. Mizutani, J.-S. Lee,C. Audigier-Valette,R. Sangha,L. Urban, J.A. Burgers,A. Pluzanski, K.H. Lee,B. Zurawski,M. Schenker, S. Peters,L.G. Paz-Ares,H. Borghaei,K.J. O’Byrne,J.R. Brahmer,R.G. Gupta

Journal of Thoracic Oncology（2023）

Cited 0|Views10
No score
Abstract
In CheckMate 227 Part 1 (NCT02477826), 1L nivolumab + ipilimumab demonstrated long-term, durable survival benefit vs chemotherapy in patients with metastatic NSCLC. Here we present updated outcomes at 6 years’ minimum follow-up, including association of OS with response/tumor burden reduction and HRQoL.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined